The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

While Verzenio, a drug in the same class, has been approved to lower the risk of early breast cancer returning, it's only for ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

Last year, the Community Oncology Alliance sued to reverse a policy that prohibits oncology practices from mailing cancer ...

In today’s “AARP Minute,” how some people taking chemotherapy drugs are saving thousands of dollars, plus a new poll shows a ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Research undertaken at the Harry Perkins Institute of Medical Research in Perth has shown that administering anti-cancer ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...